To date, the oncolytic pox virus vaccine JX-594 expressing the transgenes GM-CSF and β-galactosidase is the oncolytic virus with the most clinical evidence in HCC (see Table 1) (23). The gene discussed is CSF2; the disease is hepatocellular carcinoma.